Eisai Expands in Israeli Market With Approval of Halaven
3 Pages
English

Eisai Expands in Israeli Market With Approval of Halaven

Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Eisai Expands in Israeli Market With Approval of Halaven PR Newswire HATFIELD, England, July 10, 2012 HATFIELD, England, July 10, 2012 /PRNewswire/ -- Metastatic breast cancer treatment Halaven® (eribulin) provides a statistically significant overall survival benefit for women with the disease ®Halaven (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from the Israeli health authorities. Prior therapy should have included two common types of chemotherapy, an anthracycline and a taxane, unless patients were not suitable for these treatments. Eribulin has been proven to significantly extend overall survival in patients with [1]metastatic breast cancer, compared to other single agent chemotherapies. Following marketing authorisation, Eisai and Neopharm group, its partner in Israel, plan to launch the product by the end of Eisai's financial year 2012 (31 March 2013). Commenting on the launch of eribulin in Israel, Nick Butland, Regional Director MPBU, Eisai Europe Limited said, "The launch of eribulin in Israel will boost Eisai's geographical and patient reach in this region. Eisai's entry into this market is aligned with the company's wider strategy of increasing access to our medicines based on affordability, availability and adoption by making products available in new markets.

Subjects

Informations

Published by
Reads 22
Language English
Eisai Expands in Israeli Market With Approval
of Halaven
PR Newswire
HATFIELD, England, July 10, 2012
HATFIELD,
England
,
July 10, 2012
/PRNewswire/ --
Metastatic breast cancer treatment Halaven® (eribulin) provides a
statistically significant overall survival benefit for women with the
disease
Halaven
®
(eribulin), a novel treatment for patients with locally advanced or
metastatic breast cancer who have progressed after at least two
chemotherapeutic regimens for advanced disease, has recently received
registration approval from the Israeli health authorities. Prior therapy should
have included two common types of chemotherapy, an anthracycline and a
taxane, unless patients were not suitable for these treatments.
Eribulin has been proven to significantly extend overall survival in patients with
metastatic breast cancer, compared to other single agent chemotherapies.
[1]
Following marketing authorisation, Eisai and Neopharm group, its partner in
Israel
, plan to launch the product by the end of Eisai's financial year 2012 (
31
March 2013
).
Commenting on the launch of eribulin in
Israel
, Nick Butland, Regional Director
MPBU, Eisai Europe Limited said, "The launch of eribulin in
Israel
will boost
Eisai's geographical and patient reach in this region. Eisai's entry into this
market is aligned with the company's wider strategy of increasing access to our
medicines based on affordability, availability and adoption by making products
available in new markets."
"We are excited about the opportunity to work with Eisai to introduce Halaven
into this region", stated Mr. David Fuhrer, Chairman of the Neopharm Group.
"Working in partnership means that together we can actively introduce
innovative licensed products to meet the needs of the region and improve the
health and quality of life of patients."
The Israeli launch of eribulin will allow access for women to a treatment not
previously available to them and further supports Eisai's
human health care
(hhc
) mission to satisfy unmet medical needs and contribute to the health and
well being of people worldwide. Eisai is dedicated to discovering, developing
and producing innovative oncology therapies that can help make a difference
and impact the lives of patients and their families.
Notes to Editors
Halaven
®
(eribulin)
Eribulin is a non-taxane, microtubule dynamics inhibitor indicated for the
treatment of patients with breast cancer who have previously received at least
two chemotherapeutic regimens for metastatic disease and whose prior
therapy should have included an anthracycline and a taxane.
[1]
Eribulin belongs
to a class of antineoplastic agents, the halichondrins, which are natural
products, isolated from the marine sponge Halichondria okadai. It is believed to
work by inhibiting the growth phase of microtubule dynamics without affecting
the shortening phase and sequesters tubulin into non-productive aggregates.
Eribulin is approved in the European Union,
USA
,
Switzerland
,
Japan
, and
Singapore
. In
Europe
, eribulin is currently commercially available in
Austria
,
Denmark
,
Estonia
,
France
,
Finland
,
Germany
,
Iceland
,
Ireland
,
Italy
,
Japan
,
Luxembourg
,
Netherlands
,
Norway
,
Poland
,
Sweden
,
Switzerland
, and the
United Kingdom
.
About Eisai
Eisai is one of the world's leading R&D-based pharmaceutical companies and
has defined its corporate mission as "giving first thought to patients and their
families and to increasing the benefits health care provides," which we call
human health care (hhc). Eisai recently expanded their UK Hatfield facility
which now supports the company's growing European, Middle Eastern, African
and Russian (EMEA) business.
Eisai concentrates its R&D activities in three key areas:
Neuroscience, including: Alzheimer's disease, multiple sclerosis, neuropathic pain,
epilepsy, depression
Oncology including: anticancer therapies; tumour regression, tumour suppression,
antibodies, etc and supportive cancer therapies; pain relief, nausea
Vascular/Immunological reaction including: acute coronary syndrome, atherothrombotic
disease, rheumatoid arthritis, psoriasis, Crohn's disease
With operations in the U.S.,
Asia
,
Europe
and its domestic home market of
Japan
, Eisai employs more than 11,000 people worldwide. In
Europe
, Eisai
undertakes sales and marketing operations in over 20 markets, including the
United Kingdom
,
France
,
Germany
,
Italy
,
Spain
,
Switzerland
,
Sweden
,
Ireland
,
Austria
,
Denmark
,
Finland
,
Norway
,
Portugal
,
Iceland
,
Czech Republic
,
Slovakia
,
the Netherlands
,
Belgium
,
Luxembourg
,
Middle East
and
Russia
.
For further information please visit our web site http://www.eisai.com
About Neopharm Group
Neopharm Group, established in 1941, is one of
Israel's
leading providers of
innovative integrated solutions across the spectrums of healthcare and life
science.
Throughout the years, the group has evolved into a diversified health care
company. At Neopharm Group, we specialize in building leadership and
combining strengths in the areas of pharmaceuticals, biologic drugs, orphan
drugs, vaccines, hospital products, medical devices, medical and scientific
equipment, diagnostics, OTC, nutritionals, consumer healthcare products and
home therapy.
Neopharm is the exclusive representative and partner of leading multinational
bio-pharma and consumer healthcare brands including: Abbott, Actelion,
Alexion, Celgene, Gilead, Johnson & Johnson, Novartis Vaccines, Pfizer, Pfizer
Consumer Health among others.
Neopharm Group currently employs over 500 talented staff within 5 companies.
Neopharm holds the prestigious rank of
Israel's
second-largest marketing group
in the Israeli healthcare and life science market. Our revenues exceed
$300
million
, making us the 58th largest Israeli company as per D&B's Largest Israeli
Enterprises 2011.
For further information please visit our web site:
http://www.neopharmgroup.com
1. Cortes J, O'Shaughnessy J, Loesch D, et al. Eribulin
monotherapy versus treatment of physician's choice in
patients with metastatic breast cancer (EMBRACE): a
phase 3 open-label randomised study. The Lancet.
2011; 377: 914 -923
July 2012
/ Eribulin-UK2174